Company intelligence / Profile preview
Neuronasal
New York, New York, United Statesneuronasal.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Neuronasal has completed a pilot study demonstrating nose-to-brain delivery of N-acetylcysteine (NAC) and has received IND clearance for Phase 1 trials. NAC shows potential in treating mTBI by reducing oxidative stress and inflammation.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (e.g., N-acetylcysteine)
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
ATAI Life SciencesWeill Cornell Medical School
Beyond the preview
Go deeper on Neuronasal.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuronasal.